Chemify is a Glasgow-based deep-tech company that integrates artificial intelligence, advanced robotics, and a large vetted reaction library to design and synthesize novel molecules directly from digital code. Its core Chemputation platform enables closed-loop, automated structure–activity relationship exploration, allowing rapid generation of drug-like compounds with high potency. Current work focuses on partnering with drug discovery groups such as Lgenia to create small-molecule therapeutics for infectious diseases, notably tuberculosis. By turning chemistry into a programmable workflow, Chemify aims to shorten the time from concept to validated lead and to scale digital chemistry for medicines and advanced materials. The company was founded by chemist Lee Cronin and positions itself as a partner for pharmaceutical R&D teams seeking speed and reproducibility. Financially, Chemify has secured $3.2 million in non-dilutive grant funding from the Gates Foundation across two tranches, including a recent $1.6 million follow-on award, to advance its tuberculosis program.

Total raised

$104M

Funding rounds

5

Latest round

Grant

Latest activity

Dec 2025